Characterization of Recombinase Polymerase Amplification Primers Targeting EGFR Exon 19 Deletions for a Proposed Isothermal Lung Cancer Diagnostic Workflow
The analysis of circulating tumor DNA (ctDNA) holds significant promise for early lung cancer detection. However, current genomic screening modalities remain limited by laboratory costs and resource access. This study presents the preliminary design and experimental characterization of Recombinase Polymerase Amplification (RPA) primers designed to target the EGFR exon 19 deletion (ex19del) biomarker using synthetic control templates. This primer framework is evaluated as the foundational core for a proposed downstream workflow intended to eventually incorporate CRISPR-Cas9 specificity processing and Lateral Flow Assay (LFA) readouts. In vitro testing demonstrated successful amplification of the target sequence, with a 5 bp overlap forward primer yielding prominent amplification. Concurrently, persistent non-specific amplification was observed, establishing the necessity for subsequent enzymatic filtration. While the complete LFA readout and CRISPR-Cas9 components represent future development steps that require clinical verification in plasma samples, this work validates the operational range of the foundational amplification primers.
References
[1]
Tahayneh, K., Idkedek, M. and Abu Akar, F. (2025) NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives. Journal of Clinical Medicine, 14, Article 1025. https://doi.org/10.3390/jcm14031025
[2]
Cancer Research UK (2025) Types of Lung Cancer. https://www.cancerresearchuk.org/about-cancer/lung-cancer/stages-types/types
[3]
Tan, W.W. (2026) Non-Small Cell Lung Cancer (NSCLC). In Karim, N.A. Ed., Medscape. https://emedicine.medscape.com/article/279960-overview
[4]
Cancer Council Australia (2025) Tests to Confirm Diagnosis. https://www.cancercoun-cil.com.au/lung-cancer/diagnosis/tests/tests-to-confirm-diagnosis
[5]
Piepenburg, O., Williams, C.H., Stemple, D.L. and Armes, N.A. (2006) DNA Detection Using Recombination Proteins. PLOS Biology, 4, e204. https://doi.org/10.1371/journal.pbio.0040204
[6]
Ding, P.N., Chua, W., Bray, V. and Roberts, T.L. (2021) The Rationale and Clinical Execution of Target EGFR Testing Methodologies in Advanced Non-Small Cell Lung Cancer. Journal of Molecular Diagnostics, 23, 511-525.
[7]
Makarova, K.S., Wolf, Y.I., Iranzo, J., Shmakov, S.A., Alkhnbashi, O.S., Brouns, S.J.J., et al. (2020) Evolutionary Classification of CRISPR-Cas Systems: A Burst of Class 2 and Derived Variants. Nature Reviews Microbiology, 18, 67-83. https://doi.org/10.1038/s41579-019-0299-x
[8]
IASLC Lung Cancer News (2024) EGFR Mutations in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 20, 500-506. https://www.jto.org/article/S1556-0864(24)02531-0/fulltext
Koczula, K.M. and Gallotta, A. (2016) Lateral Flow Assays (LFAS): Principles, Structure and Applications. Essays in Biochemistry, 60, 111-120. https://doi.org/10.1042/ebc20150012
[11]
Lee, D., Ozkaya-Ahmadov, T., Chu, C., Boya, M., Liu, R. and Sarioglu, A.F. (2021) Capillary Flow Control in Lateral Flow Assays via Delaminating Timers. Science Advances, 7, eabf9833. https://doi.org/10.1126/sciadv.abf9833
[12]
Vakilian, S., Alam, K., Al‐Kindi, J., Jamshidi‐Adegani, F., Rehman, N.U., Tavakoli, R., et al. (2021) An Engineered Microfluidic Blood‐Brain Barrier Model to Evaluate the Anti‐Metastatic Activity of Β‐Boswellic Acid. Biotechnology Journal, 16, Article 2100044. https://doi.org/10.1002/biot.202100044
[13]
Kellner, M.J., Koob, J.G., Gootenberg, J.S., Abudayyeh, O.O. and Zhang, F. (2019) SHERLOCK: Nucleic Acid Detection with CRISPR Nucleases. Nature Protocols, 14, 2986-3012. https://doi.org/10.1038/s41596-019-0210-2